asthma is classically described to be eosinophilic, with Thelper-2 (Th2) lymphocytes leading to mast cell degranulation, histamine release and bronchoconstriction after allergen exposure. 3 Asthma typically develops at an early age, usually responds to anti-inflammatory and beta2-agonist medications, and thus has a good prognosis. 4, 5 COPD on the other hand is mainly tobacco-related, although air pollution and occupational exposures might play a role in its development. 3, 6 It is characterized by progressive, non-reversible airflow limitation associated with neutrophilic airway inflammation and/or emphysematous parenchyma marked by loss of alveolar elastic recoil, lung hyperinflation, and gas diffusion abnormalities. 3 COPD might not respond well to corticosteroid treatment depending on the levels of blood eosinophils; hence prognosis tends to be poor, often leading to chronic respiratory insufficiency or failure. 4, 5 Despite the apparent contrast, both can co-exist in the same patient, posing diagnostic and therapeutic challenges. This entity has been recognized by a joint committee of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the Global Initiative for Asthma (GINA) as the 'asthma-COPD overlap' (ACO) syndrome, but whether to call the overlap a syndrome is still controversial. 7, 8 Current literature
suggests that affected patients are inclined to faster disease progression, poorer quality of life, and more co-morbidities than those with either asthma or COPD alone. 9 ,10 Yet, to date the exact prevalence of ACO in the United States is unknown. Previous studies have tried to examine ACO prevalence in the United States using self-reported COPD, although this definition is inaccurate. According to international guidelines, COPD is diagnosed only when airflow obstruction is documented by spirometry. [11] [12] [13] The only US study that used spirometry defined COPD as Forced Expiratory Volume in 1 s (FEV1)/Forced Vital Capacity (FVC) <70% pre-bronchodilator administration, instead of the post-bronchodilator as suggested by the GOLD. 14 Furthermore, ACO features are yet to be fully described and there is a need to identify biomarkers that differentiate ACO from asthma and COPD. 15 Therefore, in the present study, we used a sample representative of the US adult population to (1) determine ACO prevalence in the US using a more adequate definition of COPD, (2) identify ACO predictors, (3) examine ACO association with asthma and COPD severity and (4) describe distinctive spirometry and laboratory features of ACO.
| MATERIALS AND METHODS

| Data source and study design
We used data from the NHANES conducted by the National Centre for Health Statistics (NCHS) of the Centres for Disease Control and Prevention (CDC). NHANES is a continuous cross-sectional survey of the US non-institutionalized civilian population, selected using a complex multistage sampling design to derive a representative sample of the US population. We combined 2-year data cycles from 2007 to 2012, following National Centre for Health Statistics recommendations. Of 13 387 NHANES participants of aged 40 years and older who underwent spirometry, 7570 (93.1%) had data on asthma and were included in our study. NHANES protocols were approved by the Institutional Review Boards of the NCHS and CDC and informed consent was obtained from all participants (IRB approval available at http://www.cdc.gov/nchs/nhanes/irba98.htm). Details on NHANES procedures and methods are available at http:// www.cdc.gov/nchs/nhanes/survey_methods.htm. 
| Spirometry and ACOS definition
| Eosinophil counts and exhaled nitric oxide
Complete blood count was assessed with the Beckman Coulter method and white blood cell differential used VCS technology. Exhaled nitric oxide (FeNO) was measured using a portable FDA-approved analyzer (Aerocrine NIOX MINO ® , Aerocrine AB, Solna, Sweden).
| Asthma severity and daytime oxygen therapy
NHANES participants with asthma were additionally asked about asthma exacerbations and emergency room (ER) visits for asthma in the past year. COPD participants were also asked about the use supplemental oxygen during the day.
| Demographics and comorbidities
The NHANES also collected data on age, gender, race/ethnicity, family poverty income ratio (PIR), education level, cigarette smoking, body mass index (BMI) and medical conditions or comorbidities (diabetes, hypertension, myocardial infarction (MI) or stroke and congestive heart failure [CHF]).
| Statistical analysis
Descriptive analyses were performed by asthma, COPD, as well as ACO status and the chi-square test was used to calculate P values for differences in group proportions. Crude and age-adjusted ACO prevalence were calculated for the general population and in the different subgroups. The age-standardization was done to allow comparisons independent of age using the following age groups and weights calculated from the 2010 census data (40-59 years, weight, 0.59085; and ≥60 years, weight, 0.40915). Logistic regression analysis was used to identify ACO predictors and examine ACO association with asthma severity and oxygen therapy in COPD. We compared the mean log 10 -transformed estimates of spirometry and laboratory parameters in ACO versus asthma or COPD alone using an independent t-test and the geometric means were reported after back transformation (exponentiation) of the arithmetic mean of log-transformed estimates. The analyses were performed in SAS (Version 9.4) and STATA (Version 14). The sampling design complexity was accounted for using sampling weights (WTINT2YR) and survey commands. P values <.05 were considered statistically significant in all analyses.
| RESULTS
| Description of the study population
Study sample consisted of 7570 participants. Table 1 provides a description of our study population. Briefly, compared with participant with no asthma/COPD, participants with ACO were more likely to be older, non-Hispanic White or Black, to have smoked cigarettes, or to have comorbidities (diabetes, history of MI or stroke or CHF). Compared with participants with asthma alone, those with ACO tended to be older, to be of male gender, to have smoked cigarettes and to have a history of MI, stoke or CHF. Compared with COPD alone, ACO participants were more likely to be non-Hispanic Black or Hispanic, to be obese or have comorbidities (diabetes, history of MI or stroke or CHF) ( Table 1) .
| ACO prevalence
The crude overall ACO prevalence (95% CI) after applying survey design and sampling weights was 0.96% (0.65%-1.26%). Higher crude ACO prevalence estimates were seen in participants 60 years and older ( Generalized to the US population, our sample represented about 98.58 million Americans and our results suggest that among them, 0.94 (0.62-1.26) million have ACO (Figure 1 ). 
| Factors associated with ACO
| ACO, spirometry, and eosinophils
As shown in Table 3 , the geometric means for FEV1 and PEF values were significantly lower in ACO than in asthma or COPD alone. FVC and FeNo in past smokers were significantly lower in ACO than in COPD alone, while pre-and post-bronchodilator FEV1/FVC and FEF 25-75 were significantly lower in ACO than in asthma alone (Table 4) . .0006
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Abbreviations: ACO, asthma COPD overlap; BMI, body mass index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; PIR, poverty income ratio; SE, standard error.
P values for overall differences in prevalences by strata calculated using F-test. 
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| DISCUSSION
In the United States, the prevalence of ACO was 0.96% (crude) to 1.05% (age-standardized) in the period 2007-2012. Age-standardized prevalence of ACO was higher people with low socioeconomic status and comorbidities. Among participants with asthma, increasing age and smoking were predictors of higher ACO prevalence. In participants with COPD, non-Hispanic Black race/ethnicity, obesity and history of MI or stroke were correlates of higher ACO prevalence. ACO was associated with more asthma severity and use of oxygen therapy in COPD. In spirometry, participants with ACO had worse FEV1 and PEF than those with asthma or COPD alone. Prior studies in the United States and elsewhere have reported estimates higher than ours, that is, around 2%. 9, 12, 16 A recent analysis of the BRFSS survey defined COPD by Abbreviations: ACO, asthma COPD overlap; BMI, body mass index; CHF, congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; HS, high school; MI, myocardial infarction; OR, odds ratio; PIR, poverty income ratio. OR calculated using logistic regression analysis and estimates mutually adjusted for all the other variables in the table.
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self-report and found a much higher prevalence (3.2% in participants ≥35-years old). 13 Diaz-Guzman et al. also examined the prevalence of self-reported asthma and COPD in the United States using NHANES-III (1988-1994) and reported an ACO prevalence of 2.7%. 12 Self-reported COPD is widely recognized to be inadequate, since airway obstruction should be documented by spirometry. 11 In a cohort of 2790 nurses who self-reported COPD, Barr et al. found that only 78% were confirmed cases . 17 This percentage was even lower in participants who had both asthma and COPD. 17 In Canada, self-reported COPD was compared with COPD defined using pulmonary function testing (PFT) and the COPD prevalence using PFT was found to be two to six times higher than the prevalence of self-reported COPD. 18 The study also reported minimal agreement between self-reported COPD and COPD defined using PFT, with kappa statistics ranging between 0.1 and 0.2.
18
Among participants with COPD, our reported ACO prevalence of about 12.59% (crude) or 12.49% (age-standardized) was close to estimates from the COPDGene cohort including 21 US centres which reported a prevalence of 13%. 19 They defined overlap as COPD diagnosed by spirometry with additional report of asthma diagnosed before the age 40. 19 However, our estimate for ACO prevalence in COPD was lower than the EPI-SCAN and MAJORICA in Spain which reported, respectively, 17.4% 20 and 18.3% 21 and the PLATINO study from Latin America which reported 22.8%. 22 The EPI-SCAN 20 and the PLATINO 22 both defined ACO as post-bronchodilator FEV1/FVC <0.70 and a report of previous asthma diagnosis; the MAJORICA defined ACO as diagnosis of both asthma and COPD confirmed by a physician. 21 Among people with asthma, other population studies, most of them using self-reported COPD, have reported a prevalence of ACO equal or higher than our estimates: 13.3% and 29% in the United States, 12, 23 17% in Finland 24 and 24.9% in an international study conducted in 14 countries of Europe, Asia, Africa, North and Latin America, 25 while we found 14.60% (crude) to 15.34%
(age-standardized). In the PLATINO study, which included participants ≥40 years old, the proportion of ACO among asthmatics was much higher, reporting an ACO prevalence over 51.4%. 26 Yet, none of these studies reported age-standardized prevalence estimates, which allow for more meaningful comparisons between populations with different age distributions. 27 Consistent with our findings on groups with higher ACO prevalence and on ACO predictors, the literature has widely reported that people who smoke, have obesity and/or comorbidities, are more likely to have ACO. 9, 21, 28, 29 We also found ACO associated with more asthma severity, consistent with previous observations that ACO subjects have more frequent healthcare utilization for pulmonary diseases and more expensive health care costs than those with asthma or COPD alone. 19, 20, 26, 30 How asthma might lead to ACO or COPD is not fully understood. As early as in 1961, Orie et al. formulated the 'Dutch Hypothesis', proposing that asthma and COPD might have some common genetic origins. 31 According to this hypothesis, different types of obstructive lung disease have overlapping characteristics and one (asthma) could potentially progress into another (COPD). 31 This change can be influenced by endogenous, genetic and environmental factors. 31 Recent genetic studies indicated however that asthma and COPD share very little to no genetic background. 31 Gelb and Nadel suggested that ACO may begin with asthma and that Th2 inflammation from recurrent exacerbations could lead to neutrophil elastase production and lung tissue destruction. They previously noted that some asthma patients who never smoked could have persistent expiratory airflow limitation because of loss of lung elastic recoil and develop what seems to be ACO. 33 We observed that subjects with ACO had worse lung function than participants with only one of the two obstructive conditions. This is consistent with results from studies assessing air trapping in inspiratory and expiratory computed tomography scans. 19 Interestingly, we found that the mid-flow rate (FEF25%-75%) and the FEV1/FVC ratio in ACO and in COPD were not statistically different, but lower in ACO than in asthma. Both spirometry parameters are considered to be indicators of bronchial obstruction, with FEF25%-75% being more characteristic of small airways obstruction and suggested to correlate poorly with air trapping. 34 We also found that after bronchodilator administration, FEV1/FVC was poorer in ACO than asthma. This finding suggests that worse elastic recoil may be distinctive feature of ACO, consistent with the mechanism described by Geld and Nagel. 32 However, in our analysis, FeNO levels were not associated with ACO, although FeNO is not the only marker of Th2-mediated airway inflammation. Our study has some limitations. Asthma was self-reported and could thus be subject to under or over-diagnosis or be influenced by easy access to healthcare. 35 However, self-report of asthma is widely accepted and likely valid in large-scale epidemiological studies. It is also known that a large proportion of patients with asthma have a normal lung function and using spirometry to define asthma might likely selected subjects with severe asthma and thus significantly biased our results. 36 Participants with significant comorbidities were excluded from the baseline and second spirometry. Nonetheless, the study has its strengths; especially, it provides crude and age-adjusted prevalence estimates in a very large sample that is generalizable to the U.S. adult population.
In conclusion, ACO was found in 0.96%-1.05% of the US adult population from 2007 to 2012. This is much lower than previous estimates in other US studies. ACO is associated with more asthma severity and use of oxygen therapy in COPD as well as worse lung function. Future research should include cohort studies to investigate the trend in the risk of ACO over time and factors that could potentially affect ACO trend in the different segment of the population.
